| Anti-Coronavirus Antibodies and Methods of Use K Westendorf, S Zentelis, K Muthuraman, K Jepson, E Falconer, ... US Patent App. 18/194,105, 2024 | | 2024 |
| Formulation of Resiniferatoxin B Jones, AG Nahama US Patent App. 17/569,340, 2022 | | 2022 |
| Anti-Coronavirus Antibodies and Methods of Use K Westendorf, S Zentelis, K Muthuraman, K Jepson, E Falconer, ... US Patent App. 17/192,243, 2022 | | 2022 |
| Anti-coronavirus antibodies and methods of use K Westendorf, S Zentelis, K Muthuraman, K Jepson, E Falconer, ... US Patent 11,447,541, 2022 | | 2022 |
| Anti-coronavirus antibodies and methods of use K Westendorf, S Zentelis, K Muthuraman, K Jepson, E Falconer, ... US Patent 11,370,828, 2022 | | 2022 |
| LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants K Westendorf, S Žentelis, L Wang, D Foster, P Vaillancourt, M Wiggin, ... Cell reports 39 (7), 2022 | 357 | 2022 |
| An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif D Balasubramaniam, O Schroeder, AM Russell, JR Fitchett, AK Austin, ... Journal of Lipid Research 63 (5), 2022 | 26 | 2022 |
| Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 M Dougan, M Azizad, P Chen, B Feldman, M Frieman, A Igbinadolor, ... MedRxiv, 2022.03. 10.22272100, 2022 | 77 | 2022 |
| Anticorps anti-coronavirus et procédés d'utilisation O Abiona, JS Boyles, Q Chai, K Corbett, J Davies, E Falconer, D Foster, ... | | 2021 |
| Anti-Coronavirus Antibodies and Methods of Use K Westendorf, S Zentelis, K Muthuraman, K Jepson, E Falconer, ... US Patent App. 17/116,588, 2021 | 3 | 2021 |
| Anti-coronavirus antibodies and methods of use K WESTENDORF, S ZENTELIS, K MUTHURAMAN, K JEPSON, ... | | 2021 |
| The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... Science translational medicine 13 (593), eabf1906, 2021 | 404 | 2021 |
| LY-CoV1404 potently neutralizes SARS-CoV-2 variants (preprint) K Westendorf, S Žentelis, D Foster, P Vaillancourt, M Wiggin, E Lovett, ... | | 2021 |
| Variant selection, characterization, and impact on antibody SARS-CoV-2 neutralization N Kallewaard, BA Heinz, RW Siegel, P Vaillancourt, BE Jones, ... Topics in Antiviral Medicine, 153-153, 2021 | 2 | 2021 |
| Development of a robust and semi-automated two-step antibody purification process X Yang, R Yuan, C Garcia, J Berry, D Foster, D He, GF Zhang, BE Jones MAbs 13 (1), 2000348, 2021 | 3 | 2021 |
| LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... BioRxiv, 2020.09. 30.318972, 2020 | 150 | 2020 |
| Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease RJ Benschop, CK Chow, Y Tian, J Nelson, B Barmettler, S Atwell, ... MAbs 11 (6), 1175-1190, 2019 | 32 | 2019 |
| Development of a high-throughput solubility screening assay for use in antibody discovery Q Chai, J Shih, C Weldon, S Phan, BE Jones MAbs 11 (4), 747-756, 2019 | 33 | 2019 |
| The anti-myostatin antibodies BE Jones, AI Korytko, PJ Mitchell, RC Smith, LO O'bryan, R Wang, ... | | 2018 |
| Anti-miostatin antitela J Davies, BE Jones, AI Korytko, PJ Mitchell, RC Smith, NTLO O'bryan, ... | | 2015 |
Patricia A. JenningsProfessor of Chemistry and Biochemistry, UCSD在 ucsd.edu 的电子邮件经过验证
